Intelligence Feed event · Macro · 2026-10-10

    DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth

    Question

    DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth

    Direct answer

    DaVita HealthCare (DVA) rose 1.26% to $179.25 in the latest session, outpacing the S&P 500's 0.6% gain. Market interest centers on the significant divergence between the company's valuation multiple and its projected earnings trajectory. The kidney dialysis provider currently trades at a Forward P/E ratio of 12.15 while analysts project upcoming quarterly EPS growth of 50.60% alongside 3.23% revenue expansion. For the full fiscal year, consensus models anticipate 35.16% earnings growth. The combination of modest top-line growth and accelerated EPS expansion points to structural cost stabilization, wage pressure easing across clinic operations, and improved commercial payer mix. Investors are monitoring whether the low double-digit valuation multiple will re-rate higher as quarterly earnings materialize.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-10
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth”, revision 1, evidence through 2026-10-10. https://marketontology.com/market-events/2026-10-10/davita-gains-as-forward-p-e-holds-at-12-15x-against-50-6-projected-eps-growth-08c31c

    MACRO
    DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth
    DaVita HealthCare (DVA) rose 1.26% to $179.25 in the latest session, outpacing the S&P 500's 0.6% gain. Market interest centers on the significant divergence between the company's valuation multiple and its projected earnings trajectory. The kidney dialysis provider currently trades at a Forward P/E ratio of 12.15 while analysts project upcoming quarterly EPS growth of 50.60% alongside 3.23% revenue expansion. For the full fiscal year, consensus models anticipate 35.16% earnings growth. The combination of modest top-line growth and accelerated EPS expansion points to structural cost stabilization, wage pressure easing across clinic operations, and improved commercial payer mix. Investors are monitoring whether the low double-digit valuation multiple will re-rate higher as quarterly earnings materialize.
    DVA
    Impact
    69
    OCT 10
    SIG
    87%
    DVA
    DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS Growth
    DaVita HealthCare (DVA) rose 1.26% to $179.25 in the latest session, outpacing the S&P 500's 0.6% gain. Market interest centers on the significant divergence between the company's valuation multiple and its projected earnings trajectory. The kidney dialysis provider currently trades at a Forward P/E ratio of 12.15 while analysts project upcoming quarterly EPS growth of 50.60% alongside 3.23% revenue expansion. For the full fiscal year, consensus models anticipate 35.16% earnings growth. The combination of modest top-line growth and accelerated EPS expansion points to structural cost stabilization, wage pressure easing across clinic operations, and improved commercial payer mix. Investors are monitoring whether the low double-digit valuation multiple will re-rate higher as quarterly earnings materialize.
    → Operating efficiency and treatment volume stabilization expand dialysis operating margins, supporting valuation re-rating from a 12.15x Forward P/E.
    Impact
    DaVita HealthCare (DVA) rose 1.26% to $179.25 in the latest session, outpacing the S&P 500's 0.6% gain. Market interest centers on the significant divergence between the company's valuation multiple and its projected earnings trajectory. The kidney dialysis provider currently trades at a Forward P/E ratio of 12.15 while analysts project upcoming quarterly EPS growth of 50.60% alongside 3.23% revenue expansion. For the full fiscal year, consensus models anticipate 35.16% earnings growth. The combination of modest top-line growth and accelerated EPS expansion points to structural cost stabilization, wage pressure easing across clinic operations, and improved commercial payer mix. Investors are monitoring whether the low double-digit valuation multiple will re-rate higher as quarterly earnings materialize.
    Affected
    DVA
    Transmission
    Operating efficiency and treatment volume stabilization expand dialysis operating margins, supporting valuation re-rating from a 12.15x Forward P/E.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    DVAclinic margin expansion and multiple re-ratingUp1-4wDVA trades at 12.15x Forward P/E with 50.6% quarterly EPS growth forecast.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month